Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments

被引：0

作者：

Mingot-Castellano, Maria Eva ^{[1
]}

Mellado, Patricia Alcalde ^{[1
]}

Urena, Laura Entrena ^{[2
]}

Izquierdo, Maria Cristina Pascual ^{[3
]}

Zafra, Denis ^{[4
]}

Hinryk, Mariana Canaro ^{[5
]}

Bastida, Jose Maria ^{[6
]}

Bernat, Silvia Bernat ^{[7
]}

Carballeira, Daniel Martinez ^{[8
]}

Miranda, Isabel Caparros ^{[9
]}

Garcia, Amalia Cuesta ^{[10
]}

Lakhwani, Sunil ^{[11
]}

Gonzalez, Blanca Sanchez ^{[12
]}

Maldonado, Marta Canet ^{[13
]}

Solano, Maria Carmen Gomez del Castillo ^{[14
]}

Culebra, Marta Garcia ^{[1
]}

Rodriguez, Beatriz Chiclana ^{[1
]}

Fernanadez-Villalobos, Manuel ^{[15
]}

Llorca, Paula Sanchez ^{[16
]}

Monsonis, Lola Piquer ^{[17
]}

Vazquez, Carlos Puerta ^{[18
]}

Montes, Rocio Perez ^{[10
]}

Garcia-Pallarols, Francesc ^{[19
]}

Valcarcel, David ^{[20
]}

Amador, Begona Pedrote ^{[1
]}

机构：

[1] Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Seville, Spain

[2] Hosp Univ Virgen Nieves, Granada, Spain

[3] Hosp Univ Gregorio Maranon, Serv Hematol, Inst Invest Gregorio Maranon, Madrid, Spain

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Hosp Univ Son Espases, Hematol Dept, IdISBa, Palma De Mallorca, Spain

[6] Hosp Clin Univ Salamanca, Hematol Dept, IBSAL, Salamanca, Spain

[7] Hosp Univ Plana, Villarreal, Castellon, Spain

[8] Hosp Univ Cent Asturias, Oviedo, Asturias, Spain

[9] Univ Malaga, E-29071 Malaga, Spain

[10] Hosp Sierrallana, Torrelavega, Spain

[11] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[12] Hosp Mar, Hematol Dept, Barcelona, Spain

[13] Hosp Universitari Mutua Terrassa, Terrassa, Barcelona, Spain

[14] Complexo Hospitalario Univ A Coruna, La Coruna, Spain

[15] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[16] Hosp 12 Octubre, Madrid, Spain

[17] Hosp Univ Son Espases, Mallorca, Spain

[18] Complejo Asistencial Univ Salamanca CAUSA, IBSAL, Salamanca, Spain

[19] Hosp Mar, Barcelona, Spain

[20] Hosp Univ Hebron, Dept Hematol, Barcelona, Spain

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-201847

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3948 / 3949

页数：2

共 37 条

[21] COST-EFFECTIVENESS OF ROMIPLOSTIM AS FIRST-LINE PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) TREATMENT IN ADULT SPLENECTOMISED PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS AND AS SECOND-LINE ITP TREATMENT IN ADULT NON-SPLENECTOMISED PATIENTS WHERE SURGERY IS CONTRAINDICATED IN COLOMBIA
Vargas-Valencia, J.
Garcia Perlaza, J.
VALUE IN HEALTH, 2015, 18 (07) : A842 - A842
[22] Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
Anzai, Masaki
Morikawa, Miwa
Okuno, Takehiro
Umeda, Yukihiro
Demura, Yoshiki
Sonoda, Tomoaki
Yamaguchi, Makiko
Kanno, Kiyoshi
Shiozaki, Kohei
Ameshima, Shingo
Akai, Masaya
Ishizuka, Tamotsu
MEDICINE, 2017, 96 (51)
[23] Safety and efficacy of the thrombopoietin receptor agonist Eltrombopag in patients with chronic Immune Thrombocytopenia (cITP) in routine healthcare - results of the 1st interim analysis of the non-interventional study RISA
Meyer, O.
Reiser, M.
Doerfel, S.
Schlag, R.
Kaempfe, D.
Welslau, M.
Losem, C.
Zahn, M. -O.
von der Heyde, E.
Ehrnsperger, A.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 195 - 196
[24] Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations
Narang, Arshit
Gebrael, Georges
Jo, Yeonjung
Thomas, Vinay Mathew
Li, Haoran
Fortuna, Gliceida Galarza
Sayegh, Nicolas
Tandar, Clara
Tripathi, Nishita
Chigarira, Beverly
Srivastava, Ayana
Chehade, Chadi Hage
Nordblad, Blake
Maughan, Benjamin L.
Agarwal, Neeraj
Swami, Umang
KIDNEY CANCER, 2024, 8 (01) : 135 - 142
[25] Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
Huerga, Helena
Khan, Uzma
Bastard, Mathieu
Mitnick, Carole D.
Lachenal, Nathalie
Khan, Palwasha Y.
Seung, Kwonjune J.
Melikyan, Nara
Ahmed, Saman
Rich, Michael L.
Varaine, Francis
Osso, Elna
Rashitov, Makhmujan
Salahuddin, Naseem
Salia, Gocha
Sanchez, Epifanio
Serobyan, Armine
Siddiqui, Muhammad Rafi
Tefera, Dri Grium
Vetushko, Dmitry
Yeghiazaryan, Lusine
Holtzman, David
Islam, Shirajul
Kumsa, Andargachew
Leblanc, Gamarly Jacques
Leonovich, Olga
Mamsa, Shahid
Manzur-Ul-Alam, Mohammad
Myint, Zaw
Padayachee, Shrivani
Franke, Molly F.
Hewison, Catherine
CLINICAL INFECTIOUS DISEASES, 2022, 75 (08) : 1307 - 1314
[26] Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)
McDonald, Vickie
Bradbury, Charlotte
Talks, Kate
Lowe, Gillian
Pavord, Sue
Evans, Gillian
Andiappan, Manoharan
Sandschafer, Darcie
Barbosa, Vitor Jose De Sousa
Stephens, Lorraine
Cooper, Nichola
BLOOD, 2022, 140 : 2678 - 2680
[27] Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study
Yu, Lian
Xu, Jianlin
Qiao, Rong
Zhong, Hua
Brueckl, Wolfgang M.
Zhong, Runbo
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (05) : 1108 - +
[28] Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.
Grohe, Christian
Wehler, Thomas
Dechow, Tobias
Henschke, Sven
Schuette, Wolfgang
Dittrich, Ina
Hammerschmidt, Stefan
Mueller-Huesmann, Harald
Schumann, Christian
Krueger, Stefan
Atz, Judith
Kaiser, Rolf
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis
Chen, Fei
Chen, Naifei
Lv, Zheng
Li, Lingyu
Cui, Jiuwei
JOURNAL OF CANCER, 2021, 12 (06): : 1687 - 1697
[30] Selection criteria for second-line treatments after Cyclin-dependent kinase 4/6 inhibitors failure in Hormone Receptor positive metastatic breast cancer patients: the preliminary experience of the HERMIONE-13 trial
Cazzaniga, Marina Elena
Rossi, Emanuela
Turla, Antonella
Ambroggi, Massimo
Baggi, Alice
Berardi, Rossana
Borella, Fulvio
Capici, Serena
Cicchiello, Federica
Coltelli, Luigi
De Giorgi, Ugo
Ferro, Antonella
Garrone, Ornella
Giordano, Monica
Landucci, Elisabetta
Mazzotta, Marco
Moretti, Gabriella
Palumbo, Raffaella
Pepe, Francesca Fulvia
Vici, Patrizia
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 →